Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 21, 2026

Stocks Rebound as Crude Oil Falls on Hopes for a US-Iran Deal

View original at nasdaq.com
Stocks Rebound as Crude Oil Falls on Hopes for a US-Iran Deal The S&P 500 Index ($SPX) (SPY) on Thursday closed up +0.17%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.55%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.20%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Kroger is considering significant price cuts to win back market share

    60% confidence

  • He called off a strike on Iran scheduled for Tuesday after Gulf allies asked for more time to give diplomacy a chance

    60% confidence

  • There are some good signs that a deal with Iran could be reached

    60% confidence

  • The latest US proposal has narrowed the gaps between the two sides

    60% confidence

  • Global oil inventories declined at a rate of about 4 million bpd in March and April, and the market will remain severely undersupplied until October even if the conflict ends next month

    60% confidence

  • Q1 S&P 500 earnings are projected to climb +12% y/y

    60% confidence

  • The employment side of the Fed's dual mandate is mostly stable, but right now there is a pretty significant inflation problem developing

    60% confidence

  • The current disruption has drawn down nearly 500 million bbl from global crude stockpiles, with the drawdown potentially reaching 1 billion bbl by June

    60% confidence

  • Enriched uranium must stay in Iran, as sending the material abroad would leave the country more vulnerable to future attacks by the US and Israel

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stocks Rebound as Crude Oil Falls on Hopes for a US-Iran Deal — Source | Via News | Via News